. Author manuscript; available in PMC: 2013 Aug 1.

Published in final edited form as: Am Heart J. 2012 Jul 7;164(2):251–258. doi: 10.1016/j.ahj.2012.05.010

Table 2.

Comparisons of baseline demographics, risk factors, and medications between the “definite” deterioration group and the other group.

	Definite Deterioration (n=112)	Remainder (n=673)	P
Age, yr	64.5±9.9	63.7±9.2	0.45
Female, n(%)	50 (45)	336 (50)	0.30
Body mass index, kg/m²	27.4±5.1	27.8±4.6	0.48
Heart rate, bpm	62.4±9.9	62.3±9.2	0.96
Hypertension, n(%)	54 (48)	313 (47)	0.74
Diabetes, n(%)	14(12)	81 (12)	0.89
Ethnicity, n(%)
Non-Hispanic white	41 (37)	200 (30)	0.14
Chinese-American	12 (11)	127 (19)	0.04
African-American	36 (32)	164 (24)	0.08
Hispanic	23 (21)	182 (27)	0.15
Current smoking, n (%)	19 (17)	60 (9)	0.008
LDL-cholesterol, mg/dL	118.7±32.0	118.9±31.5	0.95
HDL-cholesterol, mg/dL	50.6±14.5	51.1±15.0	0.76
Urine albumin/creatinine, mg/g	12.5±20.4	16.3±46.2	0.40
CRP^*, mg/L	2.4 (1.0–5.4)	1.6 (0.8–3.5)	0.005
Presence of coronary calcium,n(%)	65 (58)	346 (51)	0.19
LV ejection fraction,%	70.3±7.0	69.1±7.5	0.12
LV mass index, g/m²	80.0±16.6	77.6±16.4	0.17

Median (interquartile range);

CCB, calcium channel blocker; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;LDL, low-density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein; LV, left ventricular